hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06336330 id: D1699R00050 briefTitle: Real-world Study on Dapagliflozin Usage in Patients With Heart Failure (HF) in Germany acronym: EvolutionHF-DE overallStatus: NOT_YET_RECRUITING date: 2024-04-30 date: 2026-09-30 date: 2026-09-30 date: 2024-03-28 date: 2024-03-28 name: AstraZeneca class: INDUSTRY briefSummary: Heart failure (HF) is a global, public health issue that affects more than 63 million people worldwide; this burden is expected to increase substantially as the population ages. Despite advancements in treatment, a HF diagnosis still leads to significant morbidity and mortality; there is also an immense impact on patients' health-related quality of life (HRQoL). Dapagliflozin was recently granted approval for heart failure by the European Commission, regardless of ejection fraction and whether the patient has diabetes. Real-world observational data are necessary to describe dapagliflozin use in real-world settings in order to assess treatment patterns, HF symptoms and their impact on physical limitation, HRQoL and work productivity, as well as health care utilization of patients treated with dapagliflozin in this setting under local treatment standard conditions in Germany. conditions: Heart Diseases conditions: Cardiovascular Diseases conditions: Heart Failure studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 1000 type: ESTIMATED measure: Time to discontinuation of dapagliflozin measure: Reasons for discontinuation of dapagliflozin measure: Dose changes of dapagliflozin measure: Number of patients with dapagliflozin treatment interruptions measure: Treatment switches from dapagliflozin to other SGLT2i measure: Time to other heart failure treatment discontinuation measure: Number of other heart failure treatment initiation measure: Number of other heart failure treatment dosage changes measure: Number of other heart failure treatment discontinuation measure: Number of glucose lowering medication initiation measure: Number of glucose lowering medication dosage changes measure: Number of glucose lowering medication discontinuation measure: Absolute change from baseline in Kansas City Cardiomyopathy Questionnaire (KCCQ) score measure: Absolute change from baseline in Medication Adherence Report Scale (MARS)-5 questionnaire measure: Absolute change from baseline in Work Productivity and Activity Impairment (WPAI) score measure: The absolute change from baseline in occurrence of depressions in patients initiated on dapagliflozin for HF as captured by the Patient Health Questionnaire-9 (PHQ-9) measure: Healthcare resource utilisation - Number of hospitalisations since dapagliflozin initiation measure: Healthcare resource utilisation - Length of HF-related hospital stay since dapagliflozin initiation sex: ALL minimumAge: 18 Years maximumAge: 130 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06336317 id: ELIMINATE-2024 briefTitle: Effect of infLuenza vaccInation After Myocardial INfArction on Cardiac inflammaTory responsE acronym: ELIMINATE overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2027-12 date: 2027-12 date: 2024-03-28 date: 2024-03-28 name: Region Örebro County class: OTHER name: The Swedish Heart and Lung Association name: Örebro University, Sweden name: University of Cambridge briefSummary: The goal of this randomized, double-blind, placebo-controlled clinical trial is to investigate the immunological effects of influenza vaccination outside of the influenza season on arterial inflammation in patients with a recent acute myocardial infarction (AMI). The primary objective is to compare the effects of influenza vaccination to those of a placebo in reducing post-myocardial infarction coronary inflammation as measured by coronary computed tomography angiography (CCTA). The main questions it aims to answer are:
Does influenza vaccination reduce arterial inflammation as measured by CCTA at week 8 after percutaneous coronary intervention (PCI) in comparison to baseline? Does influenza vaccination modulate systemic inflammation as measured by blood biomarkers and in-vitro challenge tests at week 8 after PCI in comparison to baseline? Researchers will compare the effects of influenza vaccination with those of a placebo. conditions: Acute Myocardial Infarction conditions: Cardiovascular Diseases conditions: Inflammatory Response studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 90 type: ESTIMATED name: Influenza vaccine name: Placebo measure: The right coronary artery measure: The whole coronary tree measure: Ascending aorta measure: Interleukin 1 beta (IL-1β) measure: Tumor necrosis factor alpha (TNF-α) measure: Interleukin-2 receptor (IL-2r) measure: Interleukin Interleukin-6 (IL-6 ) measure: Ferritin measure: Troponin-I measure: N-terminal pro-B-type natriuretic peptide measure: Explorative endpoints measure: Explorative endpoints sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06336304 id: NXTPMCF-01 briefTitle: NXT Post-Market Clinical Follow-up overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2025-11 date: 2025-12 date: 2024-03-28 date: 2024-03-28 name: Laborie Medical Technologies Inc. class: INDUSTRY briefSummary: NXT Urodynamics System Post-Market Clinical Follow-up Clinical Investigation to Confirm Ongoing Safety and Performance in Urodynamic Patient Sub-Populations conditions: Urinary Incontinence conditions: Urinary Obstruction conditions: Urinary Bladder, Overactive conditions: Urinary Bladder, Neurogenic conditions: Urinary Incontinence, Urge studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 180 type: ESTIMATED measure: Assess NXT system performance measure: Assess NXT system safety measure: Assess NXT system performance sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06336291 id: PH-L19TNFLOM-01/23 briefTitle: A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence acronym: GLIOSTELLA overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2026-06 date: 2026-06 date: 2024-03-28 date: 2024-03-28 name: Philogen S.p.A. class: INDUSTRY briefSummary: The trial aims to collect safety, efficacy, exposure, dose- response, pharmacokinetic and pharmacodynamic information of the combination of L19TNF and lomustine at different dose levels in patients with Glioblastoma at progression or recurrence conditions: Glioblastoma studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 90 type: ESTIMATED name: L19TNF name: L19TNF name: L19TNF name: Lomustine name: Lomustine measure: Adverse Events measure: Serious Adverse Events measure: Unacceptable Toxicity measure: DILI assessment measure: Survival measure: Overall Survival measure: Progression Free Survival measure: Objective Response Rate measure: Disease Control Rate measure: Duration of Response measure: Time to reach maximum drug concentration [Tmax] measure: Terminal half-life [t1/2] measure: Area under the drug concentration-time curve, extrapolated to infinity [AUC] measure: Maximum drug concentration [Cmax] measure: Human anti-fusion protein antibodies (HAFA) levels against L19TNF sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06336278 id: 19/03/2024 briefTitle: Relationship Between Central Sensitization and Kinesiophobia in Knee Osteoarthritis overallStatus: COMPLETED date: 2022-10-01 date: 2023-10-01 date: 2023-12-01 date: 2024-03-28 date: 2024-04-22 name: Selda Sarıkaya class: OTHER briefSummary: Objective: The knee joint is one of most common locations in OA. In recent years, it has been accepted that there are different pain phenotypes and patient subgroups in knee OA and that central sensitization (CS) mechanisms are at the forefront in some patients. It is also known that fear of movement, known as kinesiophobia, develops in patients with chronic pain. The aim of this study is to investigate CS and kinesiophobia in patients with knee OA, their relationships with each other, and their effects on pain intensity, functional status, pain catastrophizing and depression.
Materials and Methods: Forty-two patients with knee OA and 42 healthy subjects participated in our study. Demographic data, body mass index, habits, comorbidities, medications of participants and disease duration and radiographic grade of knee OA patients were recorded. VAS was used to assess the severity of pain and WOMAC was used to assess pain and functional status in patients with OA. Algometer (pressure pain threshold measurement) and Central Sensitization Inventory were used to evaluate central sensitization in all participants. Pressure pain threshold (PPT) was measured at 3 different points: knee joint, cruris and forearm. The presence of kinesiophobia was assessed with the Tampa Scale af Kinesiophobia (TSK). Pain Catastrophizing Scale (PCS) and Beck Depression Inventory (BDI) were used to assess chronic pain related symptoms. conditions: Knee Osteoarthritis conditions: Central Sensitisation conditions: Kinesiophobia studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: CROSS_SECTIONAL count: 84 type: ACTUAL name: Pressure Algometer measure: Pain Pressure Treshold measure: Central Sensitization measure: Kinesiophobia measure: Pain Catastrophizing measure: Depression measure: Visuel Analog Scala measure: Western Ontario and McMaster Universitesies Osteoarthritis Index sex: ALL minimumAge: 45 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Zonguldak Bulent Ecevit Universitiy city: Zonguldak zip: 67100 country: Turkey lat: 41.45139 lon: 31.79305 hasResults: False
nctId: NCT06336265 id: Diaphragm ultrasound briefTitle: Diaphragmatic Ultrasound to Predict the Therapeutic Effect of High-flow Nasal Cannula Oxygen Therapy overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2024-12-31 date: 2024-12-31 date: 2024-03-28 date: 2024-03-28 name: Xingui Dai class: OTHER briefSummary: Follow-up was conducted for every patient requiring high-flow nasal cannula oxygen therapy in district 1 of the Intensive Care Department of Chenzhou NO.1 People's Hospital. Patients who met the inclusion criteria but did not meet the exclusion criteria were included for observation. Respiratory parameters, diaphragmatic activity, and variation rate of diaphragmatic thickness were recorded at the beginning of high-flow nasal cannula oxygen therapy, 1 hour after treatment, 3 hours after treatment, 6 hours after treatment, 9 hours after treatment, and 12 hours after treatment. Throughout the procedure, a panel of experts assessed whether the patient needed endotracheal intubation; If yes, the study was terminated; if no, high-flow nasal cannula oxygen therapy was continued, and observation and evaluation were continued until the end point of the study (12 hours after treatment). If patients or their family members do not want to continue to participate in the study during the study, they will be considered as withdrawal. If patients suffer from sudden malignant arrhythmia or cardiac arrest during the study, resulting in death or transfer to other hospitals or other departments during the study, patients will be excluded. Data from dropped and excluded patients were not included in the final statistical analysis. After the data of 269 patients were collected, the study was concluded, and the results and conclusions were derived by statistical analysis. conditions: Hypoxic Respiratory Failure studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 269 type: ESTIMATED name: Diaphragm ultrasound measure: Thickness and thickening fraction of Diaphragm measure: Diaphragmatic excursion measure: Respiratory rate measure: Incidence of tracheal intubation sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06336252 id: F-23059441 briefTitle: Technology Assisted Nudging to Increase Physical Activity Among Hospitalised Medical Patients acronym: SENS4ME overallStatus: RECRUITING date: 2024-04 date: 2025-12-20 date: 2026-06-20 date: 2024-03-28 date: 2024-03-28 name: Bispebjerg Hospital class: OTHER name: AAL name: Innovationsfonden briefSummary: Primary Objective To investigate if patients hospitalised for older adults with a decreased level of physical function, either related to a chronic condition e.g., COPD, Congestive heart failure, renal failure; infections; frailty and tendency of falling; orthopaedic surgery - after hip fracture will increase their time spent out of bed during hospitalisation and 3 months after discharge through visual feedback and motivational intervention about physical activities from a new mobile technology.
Hypothesis Patients hospitalised for medical disease will increase their physical activity level during hospitalisation and 3 months after discharge through visual feedback and motivational intervention from a new mobile technology. conditions: COPD conditions: Heart Failure conditions: Parkinson Disease conditions: Arthritis conditions: Old Age; Cachexia conditions: Stroke Sequelae studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: 1/1 allocation primaryPurpose: TREATMENT masking: SINGLE maskingDescription: Primary outcome (accelerometer data) blinded for the investigator and assesor. whoMasked: OUTCOMES_ASSESSOR count: 162 type: ESTIMATED name: Digital nudging intervention target to change behavior measure: Time spent out of bed measured in minutes related to the total accelerometer wear time (minutes) measure: Readmission within 90 days measure: Length of stay (days) measure: Time spent lying down, sitting, standing, and walking measured in minutes related to the total accelerometer wear time (minutes) measure: Time spent out of bed in hospital in minutes related to the total accelerometer wear time (minutes) measure: Time spent out of bed after discharge in minutes related to the total accelerometer wear time (minutes) measure: Quality of life (EQ5D-5L) measure: - In-hospital fall incidents sex: ALL minimumAge: 60 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Christian Dall status: RECRUITING city: Copenhagen zip: 2400 country: Denmark name: Christian H Dall, PhD role: CONTACT phone: 00 45 28604402 email: christian.have.dall@regionh.dk name: Morten T Kristensen, Professor role: CONTACT phone: 0045 38635000 email: morten.tange.kristensen@regionh.dk lat: 55.67594 lon: 12.56553 hasResults: False
nctId: NCT06336226 id: BB AVF one stage vs two stage briefTitle: Brachio Basilic Arterio Venous Fistula One Stage vs Two Stage overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2025-04 date: 2025-05 date: 2024-03-28 date: 2024-04-05 name: Assiut University class: OTHER briefSummary: The aim of this work was to compare primary failure rates and the primary functional patency of one-stage vs two stage brachiobasilic fistulas to compare the two surgical techniques . conditions: Arterio-venous Fistula studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: SINGLE whoMasked: INVESTIGATOR count: 50 type: ESTIMATED name: Brachio basilic arterio venous fistula one stage versus two stage measure: Comparative study between one stage brachio basilic arterio venous fistula versus two stage sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06336213 id: 20240306 briefTitle: Antibacterial Tactics Based on Presepsin Level in Thoracic Aorta Surgery Patients overallStatus: RECRUITING date: 2024-02-19 date: 2024-11-01 date: 2024-12-15 date: 2024-03-28 date: 2024-03-28 name: Petrovsky National Research Centre of Surgery class: OTHER briefSummary: According to the literature, presepsin was recommended not only as an effective indicator in the diagnosis of sepsis in intensive care units, but also as a reliable prognostic marker of postoperative inflammatory processes in cardiac surgery. Previous study carried out in Petrovsky NRCS related to biomarkers in cardiac surgery and presepsin in particular showed good sensitivity in infection complications prognosis. conditions: Aortic Aneurysm and Dissection conditions: Cardiac Valve Disease conditions: Thoracic Aortic Aneurysm conditions: Thoracic Aortic Dissection studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: NONE count: 50 type: ESTIMATED name: Ampicillin-sulbactam measure: Infectious complications rate measure: Total amount of complicated patients measure: Mortality measure: Length of hospital stay measure: Length of ICU stay measure: Multiorgan failure sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Petrovsky Research National Centre of Surgery (Petrovsky NRCS) status: RECRUITING city: Moscow zip: 119991 country: Russian Federation name: Artem Gubko, Ph.D. role: CONTACT phone: +79684241490 email: gubko@artvig.ru name: Denis Guskov, Ph.D role: SUB_INVESTIGATOR name: Boris Akselrod, Ph.D role: PRINCIPAL_INVESTIGATOR lat: 55.75222 lon: 37.61556 hasResults: False
nctId: NCT06336200 id: Karabuk-006 briefTitle: Knee Osteoarthritis and Kinesiophobia overallStatus: RECRUITING date: 2024-01-01 date: 2024-04-30 date: 2024-05-30 date: 2024-03-28 date: 2024-04-05 name: Karabuk University class: OTHER briefSummary: Kinesiophobia after total knee arthroplasty is an important parameter affecting recovery. However, the relationship between kinesiophobia and the factors it may cause is not clear. Therefore, this study aimed to examine the relationship between kinesiophobia, pain, fear of falling, mobility and proprioception in the early period after total knee arthroplasty. conditions: Knee Osteoarthritis conditions: Kinesiophobia studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: CROSS_SECTIONAL count: 56 type: ESTIMATED measure: Kinesiophobia measure: Severity of pain measure: Functional mobility measure: Proprioception measure: Fear of falling sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Ankara Pursaklar Public Hospital status: RECRUITING city: Ankara country: Turkey name: Musa Gunes, Msc role: CONTACT phone: 0 (370) 418 9081 email: musagunes@karabuk.edu.tr name: Fidan Yılmaz, Msc role: PRINCIPAL_INVESTIGATOR name: Emime Emirmahmutoğlu, Bachelors role: PRINCIPAL_INVESTIGATOR name: Buğrahan Şahin, MD role: SUB_INVESTIGATOR lat: 39.91987 lon: 32.85427 hasResults: False
nctId: NCT06336187 id: UPO 2020 02 briefTitle: European Active Surveillance of Renal Cell Carcinoma Study (EASE RCC Study) acronym: EASE overallStatus: RECRUITING date: 2018-06-01 date: 2024-12 date: 2030-12 date: 2024-03-28 date: 2024-04-10 name: Azienda Ospedaliero Universitaria Maggiore della Carita class: OTHER name: Università degli Studi del Piemonte Orientale "Amedeo Avogadro" briefSummary: The goal of this observational, prospective, multi-national clinical study is to assess overall survival of patients who are diagnosed with incidental, histologically (biopsy) confirmed, \<4 cm Renal Cell Carcinoma (RCC) and are managed conservatively with active surveillance.
The main question it aims to answer is: patients with RCC (less than 4 cm) diagnosis can be managed with active surveillance instead treated with invasive curative procedure? For all participants a percutaneous biopsy of the renal mass will be arranged in all cases to histologically confirm the diagnosis of RCC (unless a diagnostic biopsy has been acquired in the previous 6 months). As a minimum, two samples will be used for diagnostic purposes while remaining core(s) will be preserved for molecular studies.
Then, all patients will be under active surveillance, which is defined as the initial monitoring of tumor size by serial abdominal imaging (US, CT, or MRI) Follow-up visits will be scheduled 3 (optional) and 6 months after diagnosis, every 6 months up to 3 years and yearly thereafter. A follow-up visit will also be carried out at the time of progression when it occurs. Follow-up visits will include medical history and physical examination (optional), and assessment of concurrent medications, blood and urine collection and storage if participating in translational activities, cross-sectional abdominal and chest imaging exams.
Follow-up percutaneous biopsies of the renal tumor are not mandatory, but can be performed when considered clinically important. conditions: Renal Cell Carcinoma studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 400 type: ESTIMATED name: active surveillance name: molecular investigation measure: Overall Survival measure: Disease progression measure: Molecular pattern sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Ospedale Maggiore della Carità status: RECRUITING city: Novara zip: 28100 country: Italy name: Alessandro Volpe, MD role: CONTACT lat: 45.44694 lon: 8.62118 hasResults: False
nctId: NCT06336174 id: Anhui-SIA-cohort briefTitle: Cognitive Decline and Underlying Mechanisms in Symptomatic Intracranial Artery Stenosis Patients: A Cohort Study overallStatus: RECRUITING date: 2022-11-01 date: 2025-12-31 date: 2026-12-31 date: 2024-03-28 date: 2024-04-02 name: Anhui Medical University class: OTHER briefSummary: The purpose of this study is to explore the mechanism of cognitive impairment in patients with symptomatic intracranial atherosclerotic stenosis (ICAS), and further plans to explore the impact of different treatment options on cognitive function in symptomatic ICAS patients. conditions: Intracranial Atherosclerosis conditions: Cognitive Impairment conditions: Cerebrovascular Event studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 100 type: ESTIMATED name: Aspirin Tablet, Clopidogrel Bisulfate Tablets and Atorvastatin name: Endovascular therapy,Aspirin Tablet, Clopidogrel Bisulfate Tablets and Atorvastatin measure: The changes in Memory measure: Occurrence of ischemic cerebrovascular events measure: MoCA (Montreal Cognitive Assessment) measure: MMSE (Mini Mental State Examination) measure: DST (Digital Span Test; Forward and Backward) measure: The Stroop Color Test measure: CTT (Color Trail Test) measure: CDT (Clock drawing test) measure: VFT (Verbal Fluency Test) measure: HAMD (Hamilton Depression Scale) measure: HAMA (Hamilton Anxiety Scale) measure: MRI measure- resting state MRI images measure: MRI measures-structural phase MRI images measure: MRI measures-3D pCASL images measure: Ultrasound measures-MCA-PI (middle cerebral artery-pulsatility index) measure: Ultrasound measures-IMT (intima-media thickness) measure: Blood Metabolomics measures-CRP (C-reactive protiein) measure: Blood Metabolomics measures-oxLDL(Oxidized low-density lipoprotein) measure: Blood Metabolomics measures-miRNA/microRNA sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Anhui Medical University status: RECRUITING city: Hefei state: Anhui zip: 230032 country: China name: Qiang Wei, PhD role: CONTACT phone: +8618788836237 email: qiangwei_914@126.com lat: 31.86389 lon: 117.28083 hasResults: False
nctId: NCT06336161 id: ESPB versus CEI briefTitle: Comparison Between Ultrasound-Guided Erector Spinae Plane Block Versus Ultrasound-Guided Caudal Injection overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2025-04-01 date: 2025-05-01 date: 2024-03-28 date: 2024-03-28 name: Al-Azhar University class: OTHER briefSummary: Patient-controlled analgesia is typically used to relieve postoperative pain. Patient-controlled analgesia, on the other hand, is prone to opioid-related side effects. Furthermore, standard postoperative analgesia has a limited analgesic impact. If postoperative lumbosacral spine pain is not successfully treated, it can progress to chronic pain, compromising patients' quality of life.